#United States #Clinical Trials #Alzheimer's Disease #East Providence #K2 Medical Research

K2 Medical Research Launches New Clinical Trials Program in Rhode Island

K2 Medical Research, a prominent clinical research organization, is excited to announce the launch of its latest clinical trials program in East Providence, Rhode Island. This initiative is not only a testament to the organization's commitment to innovative health solutions but also marks a significant contribution to the Southern New England region's clinical research landscape.

In conjunction with the observance of Clinical Trials Day on May 20, K2 is set to provide groundbreaking research opportunities for individuals grappling with some of the most pressing health challenges, primarily focusing on Alzheimer’s disease. The company is dedicated to connecting patients with potential treatments, enhancing health outcomes both locally and globally.

The significance of Clinical Trials Day cannot be understated. It commemorates the first recognized randomized clinical trial, initiated by British naval surgeon James Lind in 1747. His research on scurvy and citrus fruit established the foundations of modern clinical research. This year’s theme underscores the passion and dedication of clinical research professionals dedicated to exploring new therapies that can revolutionize how diseases are prevented, managed, and treated. Dr. Daniel Sacchetti, Principal Investigator at K2 Medical Research, emphasized the importance of clinical trials, stating, "They allow us to explore new therapies with the potential to transform how we prevent, manage, and treat disease thereby offering hope not only to today’s patients but to future generations as well."

According to the Alzheimer’s Association 2025 Facts and Figures report, over seven million Americans currently live with Alzheimer’s disease, with nearly 12 million individuals providing unpaid care. The financial burden associated with this care is staggering, estimating $384 billion annually. Alzheimer’s has risen to become the fifth leading cause of death in the United States, outpacing even breast and prostate cancer in terms of mortality rates.

In Rhode Island, Alzheimer’s impacts approximately 22,000 individuals, which translates to 11.4% of adults aged 65 and over. K2 Medical Research's East Providence site is now actively enrolling participants in two distinct studies aimed at different stages of Alzheimer’s disease. In addition, the center is conducting an investigation into a novel medication for alcohol use disorder.

While K2 Medical Research is relatively new to the East Providence area, the team brings an impressive collective experience of over 30 years in Alzheimer’s research, with established connections within Rhode Island’s clinical environment. To celebrate Clinical Trials Day and their new site’s opening, K2 has planned a series of educational seminars, community discussions, and will participate in local summer festivals and health fairs. Visitors can expect to see Katooey, the organization’s friendly yeti mascot, making appearances to raise awareness and engage the community around these crucial health issues.

For those interested in learning more about K2 Medical Research's East Providence facility or to see if they qualify for participation in any ongoing studies, the public is encouraged to visit their website at k2med.com/k2eastprovidence or call them directly at 401-955-K2K2 (5252) to schedule a complimentary memory screening.

About K2 Medical Research

K2 Medical Research, headquartered in Orlando, Florida, stands out as a leading clinical research organization focused on advancing the field of medical science through the ethical and efficient execution of clinical trials. With a commitment to quality and innovation, K2 collaborates with various industry stakeholders to facilitate medical breakthroughs. In addition to its operations in Florida, K2 Medical Research also maintains facilities in Nashville, Tennessee, and now East Providence, Rhode Island.

For additional information about K2 Medical Research and its ongoing efforts, visit k2med.com.